Cantor Fitzgerald Reaffirms Neutral Rating for Humana (NYSE:HUM)

Cantor Fitzgerald reaffirmed their neutral rating on shares of Humana (NYSE:HUM) in a report issued on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $290.00 price target on the insurance provider’s stock.

A number of other equities research analysts have also issued reports on HUM. Barclays raised their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Wells Fargo & Company decreased their target price on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $292.26.

Humana Stock Performance

NYSE HUM opened at $259.93 on Wednesday. The business’s 50 day moving average price is $273.00 and its 200-day moving average price is $295.72. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a market cap of $31.30 billion, a P/E ratio of 23.02, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Sell-side analysts predict that Humana will post 16.11 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.32% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Norges Bank acquired a new position in shares of Humana in the 4th quarter valued at $416,202,000. Pzena Investment Management LLC grew its holdings in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after buying an additional 1,103,132 shares during the period. Boston Partners grew its holdings in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after buying an additional 893,637 shares during the period. Finally, International Assets Investment Management LLC lifted its position in Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after acquiring an additional 738,701 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.